Tag: Metabolic agent

According to the European Medicines Agency (EMA), trimetazidine, the active ingredient in Triplus 60mg, is approved for use as an add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris. It functions as a metabolic agent to improve the efficiency of heart muscle cells under conditions of reduced oxygen supply.

In September 2024, the U.S. Food and Drug Administration (FDA) approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC), classifying it as a modified amino acid. This orally administered medication addresses the progressive neurological decline seen in this rare genetic disorder.

Developed in France in the 1970s, trimetazidine is a metabolic agent used primarily as an add-on treatment for angina pectoris, a condition caused by reduced blood flow to the heart. So, what does trimetazidine do to your body? It works by directly altering cellular energy metabolism, protecting heart tissue from the damaging effects of oxygen deprivation.